Any current/future new fundraising through debt or equity?

Morepen Laboratories is currently evaluating various fundraising options for resource augmentation, including capacity expansion and working capital needs. The company is debt-free and has been approached by multiple banks for debt raising; discussions are ongoing but no final decisions have been made yet. Future capex plans amount to Rs. 200 to 250 Crores over the next 2-3 years across API, medical devices, and formulations divisions, which may require additional financing. The financial team is working on finalizing plans, and the company is open to debt or equity fundraising depending on

Any current/future capex/capital investment/strategic investment?

Capex plans span across API, medical devices, and formulations. API segment capex planned around Rs.125 Crores. Medical devices capex estimated at Rs.50 Crores. Formulation capex roughly Rs.40 Crores. Total capex plus working capital in next 2-3 years expected between Rs.200 Crores to Rs.250 Crores. Current capacity expansions funded from internal accruals (e.g., Rs.50 Crores spent in last 9 months). Additional API capacity planned: 250 KL within next 12 months. Working capital augmentation planned due to 20-25% expected growth. Company is debt-free but open to debt raising and evaluating mult

Future growth expectations in sales/revenue/volumes?

Morepen Laboratories targets a steady growth rate in revenue and volumes. API segment expected to grow at a CAGR of 17%-18%, potentially up to 20%-25% with capacity expansions. Medical devices showing strong growth, around 24% quarterly and 37% over nine months, with plans to increase distribution. Formulation business is a new growth driver, having grown 40% in the recent quarter, expected to double to around Rs.500 Crores in three years. Dr. Morepen OTC brand currently flat/fluctuating due to limited marketing investments but new innovative products are planned for launch. Overall growth tar

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA margins are expected to rise by 150 to 200 basis points annually over the next few years, moving from around 12% to potentially double digits by FY2026. Profit After Tax (PAT) is anticipated to increase from about 6% to 8-10% by FY2026, reflecting steady margin improvement. EPS for the current year is around Rs.2+ if the current quarter's performance sustains, indicating strong growth prospects. Revenue growth is targeted at 16-17% for the current year with aspirations to reach 20-25% CAGR in the next 2-3 years. Operating margins (EBITDA) are expected to stabilize in early double digits

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details on the current or expected order book or pending orders for Morepen Laboratories Limited. However, the company mentions: - Strong growth and increasing production, with a 37%-40% increase in quantity produced over nine months. - Capacity utilization is high (90%-95% in API, peak levels in devices and formulations). - Ongoing capacity expansions and investments in API, medical devices, and formulations to support growth. - Capex plans of Rs. 200-250 Crores over 2-3 years indicating preparation for increased orders. No specific figures on

IN US

Sale is live|00:00:00left today

Morepen Laboratories LtdQ4 FY25Pharmaceuticals & Biotechnology

Morepen Laboratories Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹53.2P/E: 30.1Market Cap: ₹2.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 3

→Morepen Laboratories targets a steady growth rate in revenue and volumes.
→API segment expected to grow at a CAGR of 17%-18%, potentially up to 20%-25% with capacity expansions.
→Medical devices showing strong growth, around 24% quarterly and 37% over nine months, with plans to increase distribution.
→Formulation business is a new growth driver, having grown 40% in the recent quarter, expected to double to around Rs.500 Crores in three years.
→Dr. Morepen OTC brand currently flat/fluctuating due to limited marketing investments but new innovative products are planned for launch.
→Overall growth target ranges from 20%-25% annually.
→Capacity expansions underway: Rs.125-150 Crores in API, Rs.50 Crores in medical devices, Rs.40 Crores in formulations.
→Focus on internal accruals for funding, with fundraising plans under evaluation.
→Aim to maintain and improve EBITDA and PAT margins with operational efficiencies and product mix improvements.

Margin guidance

Category 1

→EBITDA margins are expected to rise by 150 to 200 basis points annually over the next few years, moving from around 12% to potentially double digits by FY2026.
→Profit After Tax (PAT) is anticipated to increase from about 6% to 8-10% by FY2026, reflecting steady margin improvement.
→EPS for the current year is around Rs.2+ if the current quarter's performance sustains, indicating strong growth prospects.
→Revenue growth is targeted at 16-17% for the current year with aspirations to reach 20-25% CAGR in the next 2-3 years.
→Operating margins (EBITDA) are expected to stabilize in early double digits, contributing positively to bottom-line growth.
→The company is focusing on capacity expansion and new product launches to fuel future profit and earnings growth.
→Working capital and capex needs may prompt resource augmentation, but the firm remains debt-free and open to financing options.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Morepen Laboratories is currently evaluating various fundraising options for resource augmentation, including capacity expansion and working capital needs.
→The company is debt-free and has been approached by multiple banks for debt raising; discussions are ongoing but no final decisions have been made yet.
→Future capex plans amount to Rs. 200 to 250 Crores over the next 2-3 years across API, medical devices, and formulations divisions, which may require additional financing.
→The financial team is working on finalizing plans, and the company is open to debt or equity fundraising depending on market conditions and performance.
→No specific details or timelines about new fundraising through debt or equity have been disclosed yet; the company is at an evaluation stage.

Order book

Yes

→The transcript does not provide explicit details on the current or expected order book or pending orders for Morepen Laboratories Limited.
→However, the company mentions:
→ - Strong growth and increasing production, with a 37%-40% increase in quantity produced over nine months.
→ - Capacity utilization is high (90%-95% in API, peak levels in devices and formulations).
→ - Ongoing capacity expansions and investments in API, medical devices, and formulations to support growth.
→ - Capex plans of Rs. 200-250 Crores over 2-3 years indicating preparation for increased orders.
→No specific figures on outstanding or pending orders are discussed during the call.

Capex plans

Yes

→Capex plans span across API, medical devices, and formulations.
→API segment capex planned around Rs.125 Crores.
→Medical devices capex estimated at Rs.50 Crores.
→Formulation capex roughly Rs.40 Crores.
→Total capex plus working capital in next 2-3 years expected between Rs.200 Crores to Rs.250 Crores.
→Current capacity expansions funded from internal accruals (e.g., Rs.50 Crores spent in last 9 months).
→Additional API capacity planned: 250 KL within next 12 months.
→Working capital augmentation planned due to 20-25% expected growth.
→Company is debt-free but open to debt raising and evaluating multiple financing options.
→No final fundraising decisions yet; resource augmentation and capacity building are under evaluation.
→Focus on zero liquid discharge (ZLD) plant approval for environmental compliance.

How does Morepen Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Morepen Laboratories Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Morepen Laboratories Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio